Work

Focusing and sustaining the antitumor CTL effector killer response by agonist anti-CD137 mAb

Year: 2014

Type: article

Abstract: Meeting abstracts B16-derived OVA-expressing melanomas resist curative immunotherapy with either adoptive transfer of activated anti-OVA OT1 cytotoxic T lymphocytes (CTLs) or agonist anti-CD137 (4-1BB) mAb. However when acting in synergistic combination, these treatments consistently achieve tumor

Source: Journal for ImmunoTherapy of Cancer

DOI: 10.1186/2051-1426-2-s3-p95

Authors: Elixabet Bolaños-Mateo, Bettina Weigelin, Alvaro Teijeira, Ivan Martinez-Forero, Sara Labiano, Arantza Azpilicueta, Aizea Morales-Kastresana, Jose I Quetglas, Esther Wagena, Alfonso Rodriguez, Lieping Chen, Peter Friedl, Ignacio Melero

Institutions: Centro de Investigación Médica Aplicada, Radboud University Nijmegen, Universidad de Navarra, National Institutes of Health, National Cancer Institute, Yale University

Language: English

Topic: Immunotherapy and Immune Responses

Subfield: Immunology

Field: Immunology and Microbiology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $2,490

OpenAlex ID: W2131465223

FWCI: 0.282

Cites:

Cited by: 4

Related to: 10